Metastatic Gastric Cancer
Conditions
Keywords
gastric cancer, refractory, metastatic
Brief summary
Capecitabine is an oral fluoropyrimidine that has been shown to be effective in the treatment of metastatic gastric and colorectal cancer patients. On the basis of capecitabine-based chemotherapy which is accepted as a standard regimen in gastric cancer, we will perform the phase I/II study with all-oral regimen of RAD001 with capecitabine for these refractory gastric cancer patients.
Interventions
DRUGEverolimus (RAD001)
dose escalation of capecitabine, everolimus
DRUGCapecitabine
dose escalation of capecitabine, everolimus
Sponsors
Samsung Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically proven gastric cancer patients 2. Adequate organ function as defined by the following criteria: A. Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase (SGOT)) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase (SGPT)) ≤ 2.5 x local laboratory upper limit of normal (ULN), or AST and ALT less than or equal to 5 x ULN if liver function abnormalities are due to underlying malignancy B. Total serum bilirubin ≤ 3.0 mg/dL C. Absolute neutrophil count (ANC) ≥1500/µL D. Platelets ≥100,000/µL E. Hemoglobin ≥9.0 g/dL (may be transfused or erythropoietin treated) F. Serum calcium ≤12.0 mg/dL G. Serum creatinine ≤1.5 x ULN 3. Patients with CNS metastasis must have stable neurologic function without evidence of CNS progression within 8 weeks 4. Patients who have failed to at least two previous cytotoxic chemotherapy for advanced gastric cancer (adjuvant treatment will be counted as one regimen if received \< 12 months from the start of experimental treatment) 5. At least one measurable lesion by RECIST criteria 6. ECOG PS 0-2 7. Patients with informed consent
Exclusion criteria
1. Major surgery or radiation therapy within 4 weeks of starting the study treatment. 2. History of or known carcinomatous meningitis, or evidence of symptomatic leptomeningeal disease on screening CT or MRI scan. 3. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2. 4. Pregnancy or breastfeeding. 5. Prior exposure to the study drug. 6. Patients unable to swallow oral medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine maximum tolerated dose (MTD) in phase I | 1 year |
| To assess response rate in phase II | 1 year |
Countries
South Korea
Outcome results
None listed